ANSTO Radiopharmaceuticals and Industrials (ARI), a business division of the Australian Nuclear Science and Technology Organisation, congratulates SIRTeX on achieving yet another business milestone.
ANSTOs strategic partner, SIRTeX, has announced that they have been awarded approval to market SIR-Spheres (used to treat secondary liver cancer) on the European market.
According to ARI Director Dr Stuart Carr, the welcome announcement is significant in business terms for Australia. It also means that a proven and effective cancer fighting treatment is now accessible to patients in Europe as well as in Australia and adds to the range of medical options for practitioners.
"On behalf of the team at ARI, I extend our personal congratulations to SIRTeX on this milestone in their development of SIR-Spheres and their business."